{"nctId":"NCT00094497","briefTitle":"Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)","startDateStruct":{"date":"2004-06"},"conditions":["Carcinoma, Adrenal Cortical"],"count":304,"armGroups":[{"label":"EDP-M","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Etoposide","Drug: Doxorubicin","Drug: Cisplatin","Drug: Mitotane"]},{"label":"Sz-M","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Streptozotocin","Drug: Mitotane"]}],"interventions":[{"name":"Etoposide","otherNames":[]},{"name":"Doxorubicin","otherNames":[]},{"name":"Cisplatin","otherNames":[]},{"name":"Streptozotocin","otherNames":[]},{"name":"Mitotane","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed diagnosis of adrenocortical carcinoma\n* Locally advanced or metastatic disease not amenable to radical surgery resection (Stage III-IV)\n* Radiologically monitorable disease\n* ECOG performance status 0-2\n* Life expectancy \\> 3 months\n* Age ≥18 years\n* Adequate bone marrow reserve (neutrophils \\> 1500/mm3 and platelets \\> 100,000/mm3)\n* Effective contraception in pre-menopausal female and male patients\n* Patient's written informed consent\n* Ability to comply with the protocol procedures (including availability for follow-up visits)\n* Previous palliative surgery, radiotherapy or radiofrequency ablation is acceptable as long as radiologically monitorable disease is verifiable afterwards.\n\nExclusion Criteria:\n\n* History of prior malignancy, except for cured non-melanoma skin cancer, curatively in situ cervical carcinoma, or other cancers treated with no evidence of disease for at least five years.\n* Previous cytotoxic chemotherapy for adrenocortical carcinoma\n* Renal insufficiency (serum creatinine ≥2 mg/dl or creatinine clearance ≤ 50 ml/min)\n* Hepatic insufficiency (serum bilirubin ≥2 x the institutional upper limit of normal range and/or serum transaminases ≥ 3 x the institutional upper limit of normal range; exception: in patients on mitotane, transaminase levels up to 5 x the institutional upper limit of normal range are acceptable)\n* Pregnancy or breast feeding\n* Known hypersensitivity to any drug included in the treatment protocol\n* Presence of active infection\n* Any other severe clinical condition that in the judgment of the local investigator would place the patient at undue risk or interfere with the study completion\n* Decompensated heart failure (ejection fraction \\<50%), myocardial infarction or revascularization procedure during the last 6 months, unstable angina pectoris, and uncontrolled cardiac arrhythmia\n* Current treatment with other experimental drugs and/or previous participation in clinical trials with other experimental agents for adrenocortical carcinoma\n* Prisoners","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"participants who died among those randomized to first-line therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Quality of Life as Measured by QLQ-C30","description":"scale ranged from 0 to 100 with higher score meaning greater quality of life","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"21.4"},{"groupId":"OG001","value":"-7.7","spread":"25.6"}]}]}]},{"type":"SECONDARY","title":"Best Overall Response Rate","description":"RECIST 1.0 was used to evaluate response","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Disease-free Patients","description":"complete response or disease-free by time of surgery","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"TTP of Both Regimens as Second Line Treatment in Case of Failure of the Other Initial Regime","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Pharmakinetics of Mitotane (Substudy)","description":"To study the relationship between mitotane dose (daily and cumulative) and mitotane plasma concentrations using one of two pre-defined treatment regimens (high-dose and low-dose).","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Impact of Reaching Mitotane Blood Levels Between 14-20 mg/l in Both Arms on Survival and Overall Response Rate","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":86,"n":148},"commonTop":[]}}}